ArticleThe Lancet regional health. Western Pacific2021
Hepatitis B virus infection among 90 million pregnant women in 2853 Chinese counties, 2015-2020: a national observational study.
Article in The Lancet regional health. Western Pacific, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The prevalence of hepatitis B in Chinese general population from 2018 to 2022: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Pooled it
- Hepatitis B Infection Among Pregnant Women in China: A Systematic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- A longitudinal analysis of published clinical practice guidelines and their effect on disease burden.Nature communications · 2026Article
- Real-world efficacy of comprehensive measures against mother-to-child transmission of HBV in south-eastern Jiangsu, China.BMC infectious diseases · 2026Article
- Factors of post-vaccination serological testing coverage among hepatitis B-exposed children in Fujian, China: a population-based cohort study (2021-2023).Frontiers in public health · 2026Article
- Screening and validating HBV mother-to-child transmission-related lncRNAs based on the lncRNA-mRNA co-expression network.Frontiers in immunology · 2026Article
- Knowledge, perceptions, and health education needs regarding hepatitis B virus among HBsAg-positive pregnant women in Taiyuan, China: a cross-sectional study.BMC public health · 2025Article
- Progress toward elimination mother-to-child transmission of HBV in Shandong Province, China: Coverage trend in hepatitis B vaccination and HBIG administration, 2017-2024.Human vaccines & immunotherapeutics · 2025Article
- Mother-to-child transmission of hepatitis B virus, its associated risk factors, and the adoption of maternal antiviral therapy in eastern China: a retrospective cohort study.BMC infectious diseases · 2025Article
- Real-World Study for Mother-To-Child Transmission of Hepatitis B in Guangdong Province, 2021-2023.Journal of viral hepatitis · 2025Article
- Analysis of HBV infection characteristics and OBI prevalence in pregnant women: a focus on HBcAb + alone or in combination with HBeAb + subgroups in Northwest China.BMC infectious diseases · 2025Article
- The impact of gestational diabetes mellitus on pregnancy outcomes in women with hepatitis B virus: a retrospective cohort study.BMC pregnancy and childbirth · 2025Article
- Delivering integrated and standardized services to eliminate mother-to-child transmission of sexually transmitted infections: experience of the E-Clinic model in a Chinese pilot district.Health policy and planning · 2025Article
- Spatial and temporal distribution patterns and factors influencing hepatitis B in China: a geo-epidemiological study.BMC public health · 2025Article
- Characteristics and trend analysis of cancer mortality among residents of the Xizang autonomous region, 2014-2023.BMC cancer · 2025Article
- The impact of maternal HBeAg carries status and elevated ALT values on adverse outcomes: a population-based cohort study in 198,049 pregnancies.BMC pregnancy and childbirth · 2025Article
- Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012-2021: a systematic analysis.Experimental hematology & oncology · 2025Article
- Health economic evaluation of newborn hepatitis B immunization prevention strategies in Ningbo: a Markov modeling study.Frontiers in public health · 2025Article
- New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020.The Lancet regional health. Western Pacific · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChina has the largest disease burden of hepatitis B virus (HBV) infection and is considered as a major contributor to the global elimination of hepatitis B by 2030. However, the national prevalence of HBV infection among Chinese pregnant women was not reported yet. We evaluated the national and regional prevalence of HBV infection among pregnant women in China between 2015-2020, aiming to provide the latest baseline data.
methodsWe assessed the prevalence of HBV infection from data gathered through a nationwide cross-sectional study of Chinese pregnant women. Data were obtained from the National Integrated Prevention of Mother-to-Child Transmission of HIV, Syphilis and Hepatitis B Programme (iPMTCT Programme) in China, which covered all the 2856 counties from 31 provinces from 2015 to 2020. HBV infection was defined as being tested seropositive for hepatitis B surface antigen (HBsAg).
findingsA total of 90.87 million pregnant women in mainland China were testing for HBV between 2015 and 2020, with 5.60 million (6.17%, 95%CI: 6.16-6.18%) tested positive for HBsAg. From 2015 to 2020, the prevalence of HBV infection among pregnant women declined by 25.44%, from 7.30% in 2015 to 5.44% in 2020 (p for trend < 0.001), with an estimated annual percentage change (EAPC) of -5.27% (95% CI: -3.19% to -7.32%). Compared with the prevalence in 2015, reginal disparities in eastern, central, and western China were narrowed. Declines were also observed at provincial level and county level. HBV prevalence declined in most provinces (90.3%, 28/31) and counties (76.96%, 2198/2856) from 2015 to 2020. However, disparities still exist.
interpretationHBV prevalence in pregnant women in China was intermediate endemic and declined continuously from 2015 to 2020. The decline has been widespread across regions, but disparities remain. Regions with relatively higher disease burden on HBV infection should receive most attention in achieving the 2030 elimination goals.
fundingNational Natural Science Foundation of China.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.